[Form 4] MongoDB, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. (MLYS) – Form 144 filing: Adam Levy has notified the SEC of an intended sale of 12,946 common shares through Merrill Lynch on or after 28 Jul 2025 on the Nasdaq. The shares have an estimated aggregate market value of $181,803.62, implying a per-share price of roughly $14.04. Mineralys has 65.18 million shares outstanding, so the proposed sale represents about 0.02 % of the float. Levy previously sold 10,758 shares on 11 Jul 2025 for $155,454.18. The securities being sold were acquired via (1) vesting of RSUs (6,620 shares), (2) open-market purchase (3,125 shares), and (3) Employee Stock Purchase Plan allocations (3,201 shares) between Feb 2023 and Jun 2025. The filer affirms no undisclosed material adverse information. No operational or earnings data are included in this notice.

Positive

• Sale equals only ~0.02 % of outstanding shares, indicating minimal dilution or market impact.
• Transparency under Rule 144 allows market participants to anticipate the trade and incorporate it into pricing.

Negative

• Second insider sale within three weeks may be interpreted as reduced insider conviction.
• No accompanying 10b5-1 plan disclosure could prompt scrutiny over discretionary timing.

Insights

Securities Analyst

TL;DR: Small insider sale (~$182k, 0.02% float) is immaterial to valuation; signals modest diversification rather than strategic shift.

The proposed disposition of 12.9k shares by Adam Levy is minor relative to Mineralys’ 65 m share base. Recent liquidity events (10.8k shares sold earlier in July) total $337k, still well under 0.1 % of market cap. Rule 144 filings are routine for insiders unlocking equity from RSUs and ESPP programs. With no accompanying operational disclosures, the filing carries limited read-through for earnings, pipeline progress, or financing needs. I view the development as neutral for the stock; trading volumes on Nasdaq should easily absorb the sale.

Corporate Governance Expert

TL;DR: Consecutive insider sales may raise mild governance optics, but size and timing suggest ordinary portfolio management.

Investors often scrutinize insider disposition for sentiment cues. Levy’s consecutive July sales slightly exceed 23k shares over three weeks, yet remain de-minimis versus float and consistent with equity-comp plan vesting. The filing reiterates the standard Rule 144 representation that no undisclosed adverse information exists. Absence of a disclosed 10b5-1 plan could invite questions on timing, but overall governance risk is low. Impact on shareholder perception: slightly negative, but not material.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Ittycheria Dev

(Last) (First) (Middle)

C/O MONGODB, INC.

1633 BROADWAY, 38TH FLOOR

(Street)

NEW YORK NY 10019

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MongoDB, Inc. [ MDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
07/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	07/24/2025		S(1)		8,335	D	$231.99	244,892	D
Class A Common Stock	07/28/2025		S(1)		1,172	D	$241.86(2)	243,720	D
Class A Common Stock	07/28/2025		S(1)		2,071	D	$243.08(3)	241,649	D
Class A Common Stock	07/28/2025		S(1)		2,225	D	$243.78(4)	239,424	D
Class A Common Stock	07/28/2025		S(1)		2,667	D	$245.34(5)	236,757	D
Class A Common Stock	07/28/2025		S(1)		200	D	$245.91	236,557	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

2. The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $241.44 to $242.36, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

3. The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $242.47 to $243.46, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

4. The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $243.47 to $244.44, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

5. The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $244.90 to $245.77, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Remarks:

	/s/ Gahee Lee, Attorney-in-Fact	07/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Mineralys (MLYS) shares are being sold under this Form 144?

Adam Levy intends to sell 12,946 common shares.

What is the estimated market value of the planned MLYS sale?

The aggregate market value is $181,803.62.

When will the MLYS shares be sold?

The approximate sale date disclosed is 07/28/2025.

How significant is the sale relative to Mineralys’ share count?

It represents roughly 0.02 % of the 65.18 million shares outstanding.

Were other insider sales disclosed in the past three months?

Yes, 10,758 shares were sold on 07/11/2025 for $155,454.18.